Levee Medical, Inc. develops the Voro® Urologic Scaffold, a bioresorbable device designed to stabilize the bladder neck and urethra post-prostatectomy. This technology aims to reduce the incidence of urinary incontinence, a common and debilitating complication following prostate cancer surgery, thereby facilitating a quicker return to normal activities for patients.
Funding
$17.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Radical prostatectomy, a common treatment for prostate cancer, often leads to post-operative urinary incontinence, significantly impacting patients' quality of life and delaying their return to normal activities. This complication remains a major concern for patients undergoing prostate cancer surgery.
Solution
Levee Medical is developing the Voro® Urologic Scaffold, a bioresorbable implant designed to provide structural support to the bladder neck and urethra following prostate removal. The Voro® Urologic Scaffold aims to stabilize the surgical site, promoting natural healing and reducing the incidence and severity of post-prostatectomy urinary incontinence. By mitigating this complication, the device seeks to facilitate a quicker and more comfortable recovery, enabling patients to regain continence and resume their daily routines sooner. The scaffold is specifically engineered to address urinary incontinence head-on.
Target Audience
The primary target audience includes urologists and surgeons specializing in prostate cancer treatment, as well as hospitals and clinics performing radical prostatectomies.
Features
- Bioresorbable material designed for safe absorption by the body over time
- Scaffold structure provides temporary support to the bladder neck and urethra
- Designed to minimize post-operative urinary incontinence following radical prostatectomy